Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
← catalyst calendarNCT06585462 · readout in 43 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
80estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-09 | actual | When the study began enrolling |
| Primary completion | 2026-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiometabolic Disease
Interventions
- Drug: AMG 513
- Drug: Placebo
- Drug: AMG 513
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-emergent Adverse Events (TEAE)
measured Approximately 178 days (Part A) and 225 days (Part B)
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed